Drug Trial Radar · NCT07829757
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Jul 31, 2029
Study completion Jul 31, 2029
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is an unmet medical need to treat people with advanced cancer in the stomach and the junction area where the stomach joins the food pipe. These conditions are known as advanced or stomach (gastric) cancer and advanced gastroesophageal junction cancer (GEJ cancer for short). Zolbetuximab is an approved treatment in many countries for people with advanced stomach cancer and advanced GEJ cancer. Some people with these cancers have a protein called Claudin 18.2 on their tumor but they do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative). Zolbetuximab works by attaching to the Claudin 18.2 protein on their tumor. This switches on the body's immune system to attack the tumor. In India, the standard chemotherapies used are mFOLFOX6 or CAPOX. The main aim of the study is to check the safety of zolbetuximab when given with mFOLFOX6 or CAPOX chemotherapies in people in India with advanced stomach or GEJ cancer. It will also check how well zolbetuximab controls stomach cancer and GEJ cancer when given with mFOLFOX6 or CAPOX.
Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
- Metastatic Gastric Adenocarcinoma or Cancer
- Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
ZolbetuximabDrug
Participants will receive an IV infusion of zolbetuximab once every 2 or 3 weeks.
OxaliplatinDrug
Participants receiving mFOLFOX6 or CAPOX regimen of chemotherapy will receive an IV infusion of oxaliplatin once every 2 or 3 weeks.
Folinic AcidDrug
Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion of folinic acid once every 2 weeks.
5-fluorouracilDrug
Participants receiving mFOLFOX6 regimen of chemotherapy will receive an IV infusion or IV bolus of 5-FU once every 2 weeks.
CapecitabineDrug
Participants receiving CAPOX regimen of chemotherapy will receive an oral capecitabine tablet twice daily on Days 1 through 14 and Days 22 through 35 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to 32 months
- Number of participants with laboratory assessments abnormalities and/or AEsTime frame: Up to 32 months
- Number of participants with vital sign abnormalities and/or AEsTime frame: Up to 32 months
- Number of Participants at each Eastern Cooperative Oncology Group (ECOG) performance status scoreTime frame: Up to 29 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.